116,046 Shares in Annexon, Inc. $ANNX Bought by J. Goldman & Co LP

J. Goldman & Co LP purchased a new stake in Annexon, Inc. (NASDAQ:ANNX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 116,046 shares of the company’s stock, valued at approximately $663,000. J. Goldman & Co LP owned approximately 0.06% of Annexon at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after buying an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in Annexon in the fourth quarter worth $50,000. CIBC Bancorp USA Inc. bought a new stake in shares of Annexon during the 3rd quarter valued at about $31,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Annexon during the fourth quarter valued at approximately $52,000. Finally, Abel Hall LLC bought a new position in Annexon during the 1st quarter worth $61,000.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ANNX. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Citizens Jmp raised Annexon from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 13th. Needham & Company LLC lifted their target price on Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Citigroup assumed coverage on Annexon in a report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Finally, The Goldman Sachs Group initiated coverage on Annexon in a report on Tuesday, May 12th. They set a “neutral” rating and a $7.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $15.33.

Annexon Price Performance

Annexon stock opened at $4.99 on Thursday. Annexon, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $7.18. The firm’s 50 day simple moving average is $5.40 and its 200-day simple moving average is $5.44. The company has a market cap of $946.00 million, a P/E ratio of -4.30 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). On average, analysts expect that Annexon, Inc. will post -1.01 EPS for the current fiscal year.

Annexon Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.